Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors.
Publication/Presentation Date
1-1-2022
Abstract
Immune checkpoint inhibitors (ICIs) have led recent advances in the field of cancer immunotherapy improving overall survival in multiple malignancies with abysmal prognoses prior to their introduction. The remarkable efficacy of ICIs is however limited by their potential for systemic and organ specific immune-related adverse events (irAEs), most of which present with mild to moderate symptoms that can resolve spontaneously, with discontinuation of therapy or glucocorticoid therapy. Cardiac irAEs however are potentially fatal. The understanding of autoimmune cardiotoxicity remains limited due to its rareness. In this paper, we provide an updated review of the literature on the pathologic mechanisms, diagnosis, and management of autoimmune cardiotoxicity resulting from ICIs and their combinations and provide perspective on potential strategies and ongoing research developments to prevent and mitigate their occurrence.
Volume
12
First Page
940127
Last Page
940127
ISSN
2234-943X
Published In/Presented At
Irabor, O. C., Nelson, N., Shah, Y., Niazi, M. K., Poiset, S., Storozynsky, E., Singla, D. K., Hooper, D. C., & Lu, B. (2022). Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Frontiers in oncology, 12, 940127. https://doi.org/10.3389/fonc.2022.940127
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
36185227
Department(s)
Administration and Leadership
Document Type
Article